Kinaxis Launches Tariff Response Solution to Help Supply Chains Adapt to Disruption with Confidence
17.4.2025 20:30:00 EEST | Business Wire | Press release
As ongoing tariff pressures and trade uncertainty continue to reshape global supply chains, Kinaxis® (TSX:KXS), the leader in real-time supply chain orchestration, today launched Kinaxis Tariff Response - a new offering that helps companies simulate tariff exposure, run strategic scenarios, and make data-informed decisions quickly.
Built on the company’s AI-powered Maestro™ platform and delivered by Kinaxis supply chain experts, the service can be live in as few as 21 days, giving planners access to tariff modeling without the cost or complexity of building it internally. The solution meets rising demand for scenario planning - providing a faster, more accessible way for companies to shift from reactive firefighting to proactive orchestration.
While AI-powered what-if scenario planning has long been a core capability of Maestro, Kinaxis Tariff Response builds on that foundation with a focused solution for trade disruption. It combines tariff-specific inputs, sourcing logic, pricing levers, and demand modeling so companies can assess margin risk, test strategies, and evaluate trade-offs in seconds, not days or weeks.
“We’re already using Maestro scenario planning to model the impact of disruptions across our supply chain including tariffs and trade compliance policies,” said Colton Porter, manager, supply chain planning systems at furniture manufacturing and design company MillerKnoll. “It helps us evaluate sourcing options, anticipate risks, and align our team's strategy before those changes affect our margins or customer delivery commitments.”
“Global supply chains aren’t operating by the old rules anymore,” saidMark Morgan, president of global commercial operations at Kinaxis. “Tariffs are hitting faster, with broader consequences, and our data shows just how disruptive they’ve become. When trade policies shift overnight, companies need more than spreadsheets. With Kinaxis Tariff Response, they get visibility into cost, demand, and sourcing implications in real time, giving them the confidence to act with speed and precision.”
Supply chain data surging
Many Kinaxis customers already rely on Maestro’s scenario planning to stay ahead of supply chain disruptions. Over the past year, usage spiked significantly around key tariff discussions, showing how companies are turning to simulation to evaluate risks and respond faster:
- 124% scenario usage spike after the June 2024 presidential debate that first mentioned tariffs
- 112% increase following the January 2025 White House tariff memo
- 15% month-over-month rise ahead of the April 2 tariff announcements
- 24% increase in scenario planning usage quarter-over-quarter (Q1 2025 vs Q4 2024), with automotive, oil & gas, and consumer packaged goods leading the surge in anticipatory orchestration
- 4.5x daily activity in the auto sector alone during the final week of March 2025.
For more information about Kinaxis Tariff Response, please visit our website.
About Kinaxis
Kinaxis is a global leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them, in service of humanity. Our powerful, AI-infused supply chain orchestration platform, Maestro™ , combines proprietary technologies and techniques that provide full transparency and agility across the entire supply chain — from multi-year strategic planning to last-mile delivery. We are trusted by renowned global brands to provide the agility and predictability needed to navigate today’s volatility and disruption. For more news and information, please visit kinaxis.com or follow us on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250417898161/en/
Contacts
Media Relations
Matt Tatham | Kinaxis
Mtatham@kinaxis.com
+1 917 446 7227
Investor Relations
Rick Wadsworth | Kinaxis
rwadsworth@kinaxis.com
+1 613-907-7613
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership4.8.2026 12:00:00 EEST | Press release
WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/ WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership The Natural Cycles app, a Class II medical device, uses biomarker data, including temperature and heart rate data, to identify fertile and non-fertile days, helping users prevent pregnancy without hormones while also providing fertility insights. Beyond birth control, the app
Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 11:00:00 EEST | Press release
Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphatax's long-term vision for the future of tax technology. By bringing these transfer pric
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 10:10:00 EEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 10:00:00 EEST | Press release
Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 years, she has led global teams to achieve a 100% success rate from Phase 3 development through to FDA approval for multiple programs spanning oncology, immunology and respiratory medicine. In addition, she raised funds of around $400M as founder and CEO. Across her career she has contributed to 20 drug approvals, engaging
TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 10:00:00 EEST | Press release
Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network upgrades. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260803353435/en/ Adtran’s SDX 6400 Series is helping TOHKnet demonstrate how Japan’s operators can migrate to 50G PON without disrupting existing PON services. “As demand for digital services continues to grow, this trial is a key milestone for the future of fiber access in Jap
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom